Drs Shubrook and Chamberlain discuss cardiovascular risk reduction associated with SGLT-2 inhibitors and GLP-1 agonists in T2D, and advise clinicians to 'be aware.'
Dr Tyree Winters stresses the importance of identifying at-risk kids and screening often, as much as annually, to be sure that early-stage type 2 diabetes is not missed.
Drs O'Donoghue and McGuire discuss the data on the various SGLT2 inhibitors and GLP1 receptor agonists and when to consider prescribing them to your patients with diabetes.
13 min
About Medscape Diabetes & Endocrinology Podcast
From the publisher's feed
Latest medical news and features from Medscape Diabetes & Endocrinology